Acute liver failure (ALF) has a poor prognosis and, despite intensive care support, reported average survival is only 10-40%. The most common causes responsible for ALF are viral hepatitis (mainly hepatitis A and B) and acetaminophen poisoning. Hepatic transplantation is the only appropriate treatment for patients with unlikely survival with supportive care alone. Survival rates after transplantation can be as high as 80-90% at the end of the first year. However, there is a shortage of donors and is not uncommon that no appropriate donor matches with the patient in time to avoid death. Therefore, new technologies are in constant development, including blood purification therapies as plasmapheresis, hemodiafiltration, and bioartificial liver support. However, they are still of limited efficacy or at an experimental level, and new strategies are welcome. Accordingly, cell transplantation has been developed to serve as a possible bridge to spontaneous recovery or liver transplantation. Xenotransplant of adult hepatocytes offers an interesting alternative. Moreover, the development of transgenic pigs with less immunogenic cells associated with new immunosuppressor strategies has allowed the development of this area. This article reviews some of the newly developed techniques, with focus on xenotransplant of adult hepatocytes, which might have clinical benefits as future treatment for ALF.
INTRODUCTION
liver disease develops evidence of hepatic failure with encephalopathy within 8 weeks from the onset of the symptoms. The most common causes responsible for The liver is the major metabolic organ and has a central role in the homeostasis of the organism, as it is re-ALF are viral hepatitis (mainly hepatitis A and B) and acetaminophen poisoning. Other causes include toxins sponsible for the synthesis of a great variety of proteins and factors, metabolism of glucose, amino acids, choles-(e.g., Amanita phalloides), drugs (e.g., halothane), ischemia, occlusion of large (Budd-Chiari syndrome) or small terol, and drugs, and blood purification from metabolites and external toxins. The human liver has about 250 × hepatic veins, malignant infiltration, Wilson's disease, and Reye's syndrome, among others (49) . ALF presents 10 9 cells organized in about 1 million liver lobules. Hepatocytes represent the main cell population, contributwith metabolic acidosis (lactic acidosis), coagulopathy with prolonged prothrombin time, hypoglycemia, renal ing 65-70% of the total liver cells. On the other hand, many different factors, such as toxins, microorganisms, failure, sepsis, and, the most ominous, encephalopathy with cerebral edema (60). The encephalopathy degree ischemia, and neoplasia, may harm the liver (39).
Acute liver failure (ALF) is a clinical syndrome charcan vary from confusion to coma and is associated to the cerebral edema intensity. The intracranial pressure acterized by rapid loss of liver function and with high mortality. ALF occurs when a patient without previous rises and intracranial hypertension is one of the most important causes of death in ALF, together with sepsis make their widespread use in clinical settings unlikely. An alternative was whole-liver extracorporeal perfusion and multiple organ failure (13, (20) (21) (22) .
Mortality rate in ALF is high, ranging from 60% to but using a hemoperfusion column capable of absorbing leukocytes and immunoglobulin in order to avoid hyper-90%, depending on the studied series (8) even with the modern life support therapies available in intensive care acute reaction against the xenogeneic liver (37,38). However, risks remained for transmission of xenogeneic units. Estimates indicate that 1-2 million persons worldwide die each year from hepatic failure, with more than protein from the extracorporeal liver to patient blood stream and consequent immune reactions (e.g., immuno-50,000 deaths per year in the US (47) . The prognosis of patients with ALF is poor, and the outcome depends on complex deposition), and also of zoonosis. The most common method used in clinical trials to treat ALF is many characteristics such as the patient's age, disease etiology, metabolic parameters, as well as the severity the combination of plasmapheresis with hemodiafiltration using human albumin. Use of albumin dialysis is of encephalopathy and others complications. In this context, the majority of patients who progress to ALF die, necessary because most toxins removed by the liver are not hydrosoluble, and usually circulate in the cardiovasunless they undergo intervention (47) .
Because there is no satisfactory treatment for hepatic cular system bound to albumin. The more recent methods that follow this principle are MARS (Molecular Adfailure, the only recommended therapy is the substitution of the hepatic function, which can only be successsorbents Recirculating System) and Prometheus (27) . However, these methods must still be considered experifully accomplished nowadays by liver transplantation. Survival rate of patients submitted to this technique can mental as they have not improved survival in patients with ALF, despite biochemical improvement (27) . The be as high as 80-90% at the end of the first year posttransplantation (31) . However, the applicability of liver reader is invited to consult recent reviews that discuss the development of and the clinical experience with transplantation is limited in patients with ALF by shortage of organ donors, such that many patients die of rapthese devices (38,47,51). idly progressive multiorgan failure before a liver donor CELL THERAPY FOR ALF becomes available (17). Even for patients with chronic liver dysfunction, according to the "United Network for
Cell transplantation has been proposed as a promising method to support patients with liver insufficiency. As Organ Sharing," there were more than 17,000 patients on the waiting list for just 5,435 liver transplantation the liver structure usually is preserved in ALF, and the liver has potential to regenerate, cell transplantation prodonors in the US in 2005 (31) . In this article, we review the new strategies for the treatment of ALF, giving focus vides an attractive approach to support metabolic functions to buy time for liver recovery (17,39). In this view, on xenogeneic cell therapy. many investigators are evaluating the transplantation of TEMPORARY LIVER SUPPORT TECHNIQUES stem cells from many tissues or adult allogeneic or xenogeneic liver cells as a bridge for patients who are Alternatives to liver transplantation are blood purification therapies such as plasmapheresis, hemodiafiltrawaiting for a donor liver. Moreover, cell transplantation has some advantages over whole organ transplantation: tion, and bioartificial liver support. Plasmapheresis implies removal of the patient's plasma with reposition of it is a less invasive procedure and can be performed repeatedly. Identification of suitable additional sources of fresh plasma. Although it results in immediate transitory clinical improvement, it has a high cost and all the risk cells that could be transplanted into the liver should be effective for cell therapy applications. associated with transfusion of great amount of blood products. In addition, the liver has more than 500 differStem Cells: A Solution or a Problem? ent functions that cannot be replaced just by plasma exchange. Therefore, development of extracorporeal sysCell-based therapy and tissue bioengineering development allowed a possible treatment for several degentems to replace liver function has been the focus of many researchers. The bioartificial liver uses liver tissue erative diseases (46) . As current methods to support life in ALF are of limited efficacy, cell transplantation, usor adult hepatocytes to replace the synthesis and detoxification functions. However, clinical studies demoning adult hepatocytes or stem cells, has emerged as a possible bridge to liver transplantation or spontaneous strated that humans can develop immune response against swine proteins, and that anaphylactic reactions recovery (2,39). Human adult hepatocytes are hard to obtain and madid occur when patients were subjected to extracorporeal perfusion using animal livers (1) . Later, bioreactors connipulate, and the experience using these cells is very limited, which makes this method unlikely to be widetaining artificial networks where hepatocytes were allocated in the extrafiber spaces were developed (16, spread in the near future (39). Nevertheless, the experience reported to date in ALF is encouraging. Most pa-36,59). These are still highly complex structures that tients who received intrasplenic (6,15), intraperitoneal vitro must keep their new phenotype in order to be capable of performing all functions of a normal organ when (18, 25) , or direct liver infusion (15,50) of adult or fetal human hepatocytes presented improvement in encephainjected in vivo (19) . Furthermore, despite the functional recovery obtained after cell transplantation between rolopathy and biochemical tests, and some were able to be brought successfully to liver transplantation or experidents in acute liver failure models (23) , no significant improvement in hepatic function was noted when human enced spontaneous recovery. However, randomized clinical trials including higher numbers of patients are stem cells were used in a similar mouse model (39).
Another limitation with the use of uncommitted cells needed in order to prove a survival benefit. Even so, as adult or fetal human hepatocytes are hard to obtain, the is their putative capacity to generate tumors in the patient (34) . Comparative proteomic analysis of embryonic clinical results obtained to date with these cells stimulate the research with other cell types.
and tumor liver cells demonstrate that both cell populations share certain oncofetal markers, suggesting that feThe development of stem cell therapy allowed the study of other cell types, including mesenchymal, hematal liver stem cells could grow as a hepatocellular carcinoma cell (30) . Besides, these totipotent cells could topoietic, fetal, and liver stem cells (2,39). However, many questions remain to be addressed before these enter on systemic circulation and potentially populate any other organ, which might lead to unexpected results. cells can be used to treat ALF in humans. Among these points, the most crucial is the question if these stem cells Finally, the timing for cell differentiation in vitro or in vivo into adult hepatocytes might be incompatible with can differentiate in vivo into adult hepatocytes capable of performing all the functions that a normal liver does.
the urgent need for hepatic function replacement required for ALF patients. Moreover, xenotransplantation offers two additional adpatic failure, bone marrow stem cells were able to differentiate into functional hepatocytes, increase animal survantages that might be explored to enlarge the application of this transplantation modality. First, xenotransvival, and facilitate endogenous hepatocytes to repopulate liver tissue (29) . Interestingly, fetal hepatocytes have plantation might not be susceptible to certain human viruses, like hepatitis and HIV. The second benefit is also been regarded as potentially suitable to be used as donor cells in ALF. In contrast to adult hepatocytes, fethat xenotransplantation might offer a way for "gene delivery" that could overcome some current hurdles to tal hepatocytes are thought to be highly proliferative, which may facilitate engraftment and expansion of gene therapy, because genetic changes could be carried out to egg embryo genome (24) . For many years, liver transplanted cell population (3). Recent work demonstrated that rat fetal liver cells repopulate two thirds of support systems have been developed to supply the liver functions, mostly as a bridge to transplantation, but a liver after partial hepatectomy in normal rats, and that transplanted cells are morphologically and functionally these systems are not yet clinical standard therapy, as discussed before. The therapeutic option of swine organ integrated into the host liver and indistinguishable from host hepatocytes, except for the marker gene (40,41).
xenotransplantation to humans has being investigated (10). However, the clinical application of this practice is Nonetheless, some researchers have presented controversial data. Recently, Sharma and coworkers (52) demlimited by severe immune response of the recipient against the donor organ, resulting in immunological deonstrated that hepatic stem cells have a limited repopulation capacity associated with an immature hepatic struction of the graft. This response toward a xenograft is complex and comprises initially two antibody-mediphenotype. In fact, stem cells transplanted to liver form "clusters," but not a real hepatic tissue with normal arated processes, termed hiperacute rejection (HAR) and acute humoral xenograft rejection (AHXR) (64) . The chitecture (39). In addition, spontaneous cell fusion was observed between hepatocytes and hematopoietic or emxenoreactive natural antibodies that mediate both HAR and AHXR are directed against the ubiquitous terminal bryonic stem cells. These cells adopt the phenotype of the recipient cells, which, without detailed genetic analcarbohydrate epitope Galα1-3Galβ1-4GlcNAc (α1,3Gal) that is present on the glycoproteins and glycolipids of ysis, might be interpreted as differentiation into adult tissue cells (57, 65) . It is important to point out that cells porcine vascular endothelium. As many microorganisms also express α1,3Gal, humans are constantly exposed to expanded and differentiated into adult hepatocytes in these antigenic determinants. For this reason, humans screening for possible exogenous microorganisms. Although the risk of swine endogenous retrovirus transmispresent these natural antibodies in the sera (10,64).
The development of transgenic pigs was an important sion still exists (56), among 160 patients treated with tissues of swine origin no swine retrovirus infection was step towards the control of hyperacute and vascular rejections. Xenotransplants to animal models using livers detected even 10 years after exposure (43). Another study with 13 recipients of embryonic porcine mesenceobtained from pigs expressing human complement regulatory proteins (5,11), whose organs are protected phalic tissue or extracorporeal perfusion with transgenic pig livers also found no evidence of porcine endogenous against the recipient's complement system, or from pigs that have the α1,3-galactosltransferase gene disrupted retroviruses (PERV) sequences by PCR testing peripheral blood mononuclear cells (44) . and, therefore, do not express α1,3Gal (26), demonstrated longer xenograft survival (10). Moreover, a reTransplantation of isolated xenogeneic hepatocytes instead of whole liver has been proposed and would concent study demonstrated that transgenic pigs that expresses HLA-E/human β2-microglobuin are protected stitute an unlimited supply of cells to treat severe diseases (55) . Besides that, the use of adult hepatocytes is against NK cell-mediated cytotoxity and this new approach has important implications for the generation of an interesting option because there is no endothelium related with xenogeneic whole organ transplantation (7). transgenic pigs as organ or tissue donors for clinical xenotransplantation (62). Modulation of the recipient
In 1995, an original work demonstrated that rat hepatocytes could reconstitute the liver of hepatectomized mice immune response and anticoagulation therapy prolong the survival of the xenograft and avoid intravascular (45). In the same way, highly differentiated human adult hepatocytes could repopulate the immunotolerant RAGthrombosis of the graft (10).
The risk of cross-species infection or zoonosis (also 2 knockout mouse liver (12), confirming the possible use of adult hepatocytes for xenotransplant. Mai and cocalled xenozoonosis or direct zoonosis) is another hurdle to xenotransplantation (14). Nevertheless, this risk can workers (32) demonstrated that the injection of human hepatocytes in mice with ALF was able to provide lifebe minimized by housing the animals in an ambient environment with efficient barrier methods and stringent supporting and liver-specific function requiring no im- Figure 1 . The xenotransplant of hepatocytes in acute liver failure. Acute liver failure patients will be subjected to knock-out pig hepatocyte transplantation. As illustrated, xenotransplanted hepatocytes will live together with normal cells (A) or at least have a transient survival allowing the multiplication of host cells (B). In both cases a better survival is expected. Figure 2 . Development and application of xenogeneic transplantation in acute liver failure. Adult hepatocytes will be isolated from porcine livers obtained from α1,3-galactosyltransferase knockout pigs. These cells will be transplanted into the liver of acute liver failure animal models where we expect a higher survival (preclinical trials). The ideal number of injected cells will be experimentally determined. The porcine cells may be frozen or directly transplanted to human with acute liver failure (clinical trials).
munosuppressive therapy. Similarly, the transplantation encapsulated (33) adult porcine hepatocyte transplantation into the peritoneum of rats with ALF resulted in of immortalized human hepatocytes into the spleens of severe combined immunodeficiency mice with acetsignificant reduction in the mortality rate. The use of porcine hepatocytes for cell xenotransplantation has also aminophen-induced ALF resulted in increased survival (58) . However, the use of immunoregulators could have been tested in chronic liver failure models where xenogeneic hepatocytes were able to integrate the recipient applicability on xenogeneic implantation on the liver. A recent work using a mouse model of ALF treated with liver and produce albumin for more than 50 days (53) . The use of hepatocytes obtained from pigs expressing anti-Fas antibody transplanted with rat hepatocytes suggested that the induction of cell proliferation blockade human complement regulatory proteins or not expressing antigen on their surface may confer additional adin recipient livers could promote sufficient engraftment of transplanted hepatocytes to allow transient or definivantages to the xenogeneic transplanted cells. The use of siRNA on porcine hepatocytes to the α1,3-galactosyltive treatment of liver failure (61) . In addition, the administration of daclizumab, a humanized anti-IL2 receptransferase gene result in cells resistant to natural antibodies in human serum (63), indicating that they could tor α chain antibody, in rats with ALF contributed to improve the survival of animals that received rabbit hebe resistant to HAR during an interspecies transplantation. In addition, cell transplantation would be a far patocytes (42).
Porcine hepatocytes may also be a source for cell more simple technique than the transplant of a whole organ, a principle that should be taken into account in xenotransplantation. Encapsulated porcine hepatocytes transplanted into the rat peritoneum remained viable and the treatment of critical patients. To date, however, there are few data about cellular functional 1 month after the procedure (4), and porcine hepatocytes directly injected into the spleen of monkeys xenotransplantation of knockout pigs in ALF models, and more studies in this area are necessary. The expectawere able to engraft and survive (35) , suggesting that these cells could be used for the treatment of ALF. In tion is that xenotransplantation of swine adult hepatocytes to failing livers may improve their function and fact, transplantation of either encapsulated (48) or non- 
